Special Episode: SRP-9001 Approved As First Gene Therapy for Duchenne Muscular Dystrophy
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Natalie Goedeker, CPNP. [LISTEN TIME: 12 minutes]
A special episode of the NeurologyLive®
The Mind Moments® podcast features exclusive interviews with leaders in the field discussing the latest research and disease management strategies across the breadth of neurology, including epilepsy, multiple sclerosis (MS), Parkinson disease, dementia, sleep disorders, and more.
This episode, "SRP-9001 Approved As First Gene Therapy for Duchenne Muscular Dystrophy," features an exclusive interview with Natalie Goedeker, CPNP, a nurse practitioner in neurology in the Neuromuscular Division at Washington University in St Louis. SRP-9001 (Elevidys; Sarepta), also known as delandistrogene moxeparvovec, was approved for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene aged 4 to 5 years, based on data from the 3 clinical trials.1
EPISODE BREAKDOWN
- 0:30 – SRP-9001 (Elevidys; Sarepta) is approved for DMD
- 1:35 – Natalie Goedeker, CPNP, on the approval
- 3:05 – Efficacy of SRP-9001
- 4:00 – Goedeker on pieces of efficacy data released
- 4:45 – Currently available therapies for DMD
- 5:35 – Goedeker on role of SRP-9001 in treatment landscape
- 6:55 – Safety data of SRP-9001
- 8:00 – Goedeker on safety considerations of which prescribing clinicians should be aware
REFERENCE
1. Sarepta Therapeutics announces FDA approval of Elevidys, the first gene therapy to treat Duchenne muscular dystrophy. News release. June 22, 2023. Accessed June 22, 2023. https://www.businesswire.com/news/home/20230622454844/en/
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
